Cancer-focused genetic testing services provider NeoGenomics has agreed to acquire Clarient, the life sciences business unit of GE Healthcare, for approximately $275m.

Under the deal, NeoGenomics will also buy Clarient’s wholly owned subsidiary Clarient Diagnostic Services that offers comprehensive cancer diagnostic testing to hospitals, physicians and the pharmaceutical industry.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

NeoGenomics chairman Douglas VanOort said: "Our vision is to become America’s premiere cancer testing laboratory, and this acquisition is a major step forward in achieving that vision.

"We have always respected Clarient’s outstanding capabilities, and are very pleased to be able to combine them with our own outstanding service offering."

"We believe the business will benefit from the focus that will come from being part of NeoGenomics."

With this development, NeoGenomics is expected to strengthen its offering of innovative cancer diagnostic tests, and also to increase its pre-science in pharmaceutical clinical trials and research market.

Clarient’s pathology services and capabilities in the analysis of solid tumour cancers of the breast, colon and lung are expected to support NeoGenomics’ molecular testing services and expertise in testing for hematologic cancers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Clarient Diagnostic Services CEO Cindy Collins said: "We believe the business will benefit from the focus that will come from being part of NeoGenomics, while allowing GE Healthcare Life Sciences to focus on its core long-term growth areas in bioprocessing, cell therapy and disease imaging."

Clarient reported revenue of $127m and adjusted EBITDA of $13m last year. The company currently employs 415 people.

In September, NeoGenomics entered a national group purchasing agreement with Premier in order to offer cancer genetics testing services to 3,600 hospitals.

With the three year agreement, NeoGenomics will support premiere member hospitals, cancer centres, pathology groups, and oncology/physician providers nationwide.